December 18, 2001: Home Health VNA Provides Home Care for Children in Need with Baxter International Foundation Grant
December 17, 2001: Baxter Donates $2 Million to Address the Mental and Physical Health-Care Needs of Those Affected by the Tragedies of September 11
December 13, 2001: RMS Disease Management Inc. to Coordinate Care for Empire Blue Cross and Blue Shield
December 12, 2001: Baxter, Nutricia and Andreas Rudolph Form a Joint Venture to Serve the Growing Homecare Market in Germany
December 11, 2001: Baxter´s HomeChoice Pediatric Dialysis System Receives Market Clearance From FDA
December 10, 2001: Cerus and Baxter Present Phase III Results for the INTERCEPT Platelet and Plasma Systems at the American Society of Hematology Meeting
December 10, 2001: Cerus and Baxter Report Results in Trial of INTERCEPT Red Blood Cell System
December 10, 2001: Baxter and Haemonetics Sign Agreement for Baxter/Cerus Pathogen Inactivation Technology for Platelets
December 6, 2001: Helping Hands to Provide Emergency Medical Fund with Baxter International Foundation Grant
December 4, 2001: Porter-Leath Children´s Center to Provide Dental Services for Low-income Youth with Baxter International Foundation Grant
November 30, 2001: Baxter to Expand Offering of Patient Safety Technologies with the Acquisition of AUTROS Healthcare Solutions Inc.
November 29, 2001: Baxter Releases New Software for Its Colleague Line of Infusion Pumps
November 28, 2001: Baxter Announces Agreement With Families Affected by Recent Hemodialysis Deaths in Spain
November 28, 2001: Baxter Confirms Role in Smallpox Vaccine Production
November 28, 2001: Baxter Declares Annual Dividend
November 15, 2001: Saint Alban´s Child Enrichment Center Receives $46,000 Grant From Baxter International Foundation
November 5, 2001: Following Extensive Investigation, Baxter Identifies Probable Cause of Recent Hemodialysis Patient Deaths
November 1, 2001: Baxter Completes Its Acquisition of ASTA Medica Oncology
November 1, 2001: Baxter Schliesst Ãœbernahme Von ASTA Medica Oncology AB
October 18, 2001: Baxter Delivers Strong Third Quarter Performance, With Sales Increasing 13 Percent, Earnings Up 18 Percent
October 17, 2001: Cerus and Baxter Report Positive Results in Trial of INTERCEPT Red Blood Cells
October 16, 2001: Baxter Acquires Proprietary Recombinant Erythropoietin Drug
October 15, 2001: Cerus and Baxter Report Inactivation of Trypanosmoa CruziI Parasite
October 15, 2001: Baxter Urges Comprehensive Scientific Analysis of Hemodialysis Treatment Safety
October 15, 2001: Baxter and International Society of Nephrology Launch Renal Discoveries Extramural Grant Program to Promote Scientific Discovery in the Field of Kidney Disease
September 10, 2001: Baxter Receives FDA Approval for Third Manufacturing Suite at Thousand Oaks
August 20, 2001: Baxter Healthcare Corporation Completes Acquisition of Cook Pharmaceutical Solutions
August 17, 2001: Cerus and Baxter Report Positive Phase III Results for the INTERCEPT Platelet System
August 17, 2001: Cerus and Baxter Report Primary Endpoint Met in U.S. Phase III Trial of the INTERCEPT Plasma System
August 9, 2001: FDA Advisory Panel Unanimously Recommends Approval of Extraneal (7.5% Icodextrin), Baxter´s Peritoneal Dialysis Solution
August 8, 2001:Baxter´s New e-Chair To Entice Blood Donors With Multimedia Entertainment and Internet Access
August 7, 2001:Baxter Renforce Sa Position En Oncologie Par L´Acquisition De Asta Medica Oncology
August 7, 2001: Übernahme Von ASTA Medica Oncology Stärkt Position Von Baxter Im Onkologie-Bereich
August 7, 2001: Baxter To Advance Its Position in Oncology with Acquisition of ASTA Medica Oncology
August 2, 2001: Baxter Addresses Bioethics, Climate Change and Charitable Giving in Its 2000 Sustainability Report
July 30, 2001: National Urban League Honors the Baxter International Foundation for Exemplary Local Community Leadership
July 19, 2001: Baxter´s Sales Grow 10 Percent, Earnings Per Share Advance 11 Percent in Second Quarter
July 18, 2001: Baxter Receives European Licensure for Ceprotin, a Treatment for Protein C Deficiency
July 16, 2001: Cerus and Baxter Report Phase IIIa Results for the Intercept Plasma System
July 16, 2001: Cerus and Baxter Report Additional Intercept Platelet Data from European Phase III Trial
July 12, 2001: Baxter to Further Increase Manufacturing Capacity for Therapeutic Proteins
June 28, 2001: Landmark Dialysis Study Findings Could Greatly Simplify Treatment of Kidney Disease with Peritoneal Dialysis
June 27, 2001: Baxter´s Advoy e-Care Platform Enables Clinicians to Monitor Patients Via the Internet for Better Disease Management
June 20 , 2001: Baxter Healthcare Corporation to Acquire Cook Pharmaceutical Solutions
June 7, 2001: Baxter Healthcare Corporation to Receive Prestigious Shingo Prize for Excellence in Manufacturing
May 17, 2001: Baxter International Receives DePaul University´s Business Ethics Award for 2001
May 16, 2001: Baxter Taps Convertible Debt Market to Cost-Effectively Refinance Short-Term Debt
May 15, 2001: Baxter Announces Convertible Debt Offering
May 10, 2001: Baxter to Expand Recombinant Protein Manufacturing Facility
May 1, 2001: Baxter International Inc. Showcases Growth Initiatives at Annual Meeting of Stockholders
April 20, 2001: Baxter Healthcare Corporation Receives Award for NeisVac-C from Technology Council of Maryland
April 19, 2001: Baxter Continues Growth Momentum in First Quarter with 11 Percent Increase in Sales, 12 Percent Growth in Earnings and 9 Percent EPS Growth
April 17, 2001 : Baxter Healthcare Corporation and Genetics Institute, Inc. Announce Settlement
March 26, 2001: Baxter International Names Chief Scientific Officer
March 20, 2001: Baxter International Enhances Distribution Channels
March 19, 2001: Baxter Grants Stock Options to More Than 41,000 Baxter Team Members
March 15, 2001: Baxter Executives Highlight Growth Initiatives at Investor Conference
March 12, 2001: U.S. Pharmacopeia and Baxter Healthcare Corporation Announce Joint Marketing Agreement to Promote USP´s MedMARxSM Program
March 9, 2001: Baxter and Pharming Start Clinical Study with Recombinant Human C1 Inhibitor for Hereditary Angioedema
March 7, 2001: Baxter Announces Plans for New Facility for Production of Recombinant and Cell-Culture Derived Vaccines
March 6, 2001: Baxter Healthcare Launches Large-Scale Education Initiative for Patients with Advanced Kidney Disease
February 28, 2001: Baxter´s Board of Directors Approves Two-For-One Common Stock Split
February 27, 2001: Baxter International Names Three New Corporate Officers
February 19, 2001: FDA Accepts Baxter´s New Drug Application Filing for Icodextrin Peritoneal Dialysis Solution
February 1, 2001: Baxter Acquires Sera-Tec Biologicals
January 31, 2001: Baxter´s Senior Management Team Voluntarily Converts Restricted Stock to Options to Better Align Incentives Directly With Shareholder Interests
January 30, 2001: Welch Allyn Protocol Inc. and Baxter Healthcare Corporation Sign Agreement to Interface Infusion Therapy and Patient Monitoring Technologies
January 25, 2001: Cerus and Baxter Complete Enrollment in U.S. Phase III Trial of Intercept Platelet System
January 25, 2001: Baxter Continues Momentum with Strong Growth in Earnings and Sales. Baxter´s Earnings Escalate 17 Percent in the 4th Quarter and for Full-Year 2000
January 23, 2001: Baxter Launches New Leukoreduction Filter for Whole Blood
January 02, 2001: Cerus and Baxter Submit CE Mark Application for European Approval of the Intercept Platelet System
Print this page
